Slingshot members are tracking this event:

Phase 1/2 clinical trial preliminary data of AMT-060 for hemophilia B due January 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details In early January 2016, the Company plans to release preliminary, top-line data for the two patients who will have completed at least 12 weeks of treatment follow-up. The data readout will include safety results and FIX expression levels. No additional data from the remaining cohort patients or other measures of the trial will be reported at that time. The Company expects to report on the full results of the first cohort at a scientific conference during 1H 2016.
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2, Amt-060, Hemophilia B